The relative efficacy and toxicity of the chemotherapeutic dation chemotherapy with ADE (9%) than with DAT (6%) (P ! .06). Patients receiving DAT took slightly but significantly agents thioguanine (6TG) and etoposide (VP16) were assessed by a randomized comparison of the DAT (daunorulonger to recover from neutropenia and thrombocytopenia but the median number of days in hospital were similar in bicin, cytarabine, thioguanine) versus ADE (daunorubicin, cytarabine, etoposide) regimens in the Medical Research each group. ADE patients experienced slightly more severe nonhematologic toxicity. There was also no significant difCouncil's 10th acute myeloid leukaemia trial (MRC AML 10), which was open to patient entry from May 1988 to April ference between the groups in the longer-term measures of efficacy: disease-free survival at 6 years from CR was 42% 1995. In this, the largest reported trial of AML therapy to date, 1,857 eligible patients, mostly less than 56 years old, (Ô4) for DAT and 43% (Ô4) for ADE (P ! .8); relapse rate at 6 years was 50% (Ô4) for DAT and 49% (Ô5) for ADE (P ! were randomized: 929 (including 143 children under 15 years old) were allocated to DAT and 928 (143 children) to ADE.
A
Therefore, one aim of the MRC AML10 study was to compare the relative efficacy and toxicity of thioguanine with LTHOUGH a substantial minority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) and then appear to be cured, the majority are still not etoposide in the induction chemotherapy regimen in patients with AML aged less than 56 years old. The results are recured. Even in children or young adults about 10% to 20% have resistant disease and never achieve CR, another 5% to ported here. 10% die from infection or hemorrhage during aplasia, and
MATERIALS AND METHODS
even after remission has been achieved at least half (or more, at older ages) relapse and die. Therefore, trials are needed
Patients. Between May 1988 and April 1995, a total of 1, 966 of treatments that might avoid primary resistance, limit early patients was entered into the MRC AML 10 trial from 163 centers in the United Kingdom, Republic of Ireland, and New Zealand (Tatoxicity, and/or prevent relapse. In particular, toxicity has ble 1), and 1,857 are evaluable. The trial was primarily designed for usually been assessed only by retrospective analysis of small patients aged up to 55 years, though older patients could be entered groups of patients, 1 but both toxicity and efficacy should be if they were considered suitable for the intensive AML10 therapy.
evaluated in large prospective trials.
Based on UK incidence figures, recruitment to the trial represents It has been hypothesized 2 that failure of therapy was often about 40% of adults aged 15 to 55 and 75% of children (age 0 to due to the selection and growth of drug resistant clones 14) with AML in these countries.
arising by spontaneous mutation. Hence, studies were underIn addition to patients with AML, children with aggressive myelotaken to evaluate the delivery of multiple drugs simultanedysplasia (refractory anemia with excess blasts in transformation ously, the addition of high-dose cytarabine, and the introduc- [RAEB-t] ) were also eligible if AML type therapy was deemed tion of newer drugs such as etoposide to induction appropriate. Secondary AML cases, either following prior cytotoxic regimens. 3, 4 Perhaps partly because of the small size of these chemotherapy or radiotherapy for other tumors or subsequent to a preceding hematologic disorder, were also eligible for entry.
studies, however, they produced no clear improvements in
The trial had two randomizations (Fig 1) ; the first was between the rate of remission induction or survival. In many coundaunorubicin, cytarabine, and thioguanine (DAT) and daunorubicin, tries, therefore, the standard induction therapy remains daucytarabine, and etoposide (ADE) as induction regimens and the secnorubicin and cytarabine. However, in the United Kingdom Medical Research Council (MRC) trials, the standard chemotherapy induction regimen has been DAT (daunorubicin, had completed four courses of chemotherapy, and were not randomized with respect to A-BMT versus stop. The results of the second randomization will be reported separately. had commenced (Table 1) . Eight patients who were rediagnosed as with the outcome of 1,857 eligible patients, 929 of whom were 100 mg/m 2 IV (1-hour infusion) days 1 through 5. DAT 3 " 8: As DAT allocated to DAT and 928 who were allocated to ADE. cortisone was given as part of each course to a total of five doses. and, for remitters, the relapse risk is the cumulative probability of relapse, ignoring (ie, censoring) at death in CR. If CR was not achieved after two courses of DAT or ADE, and a further attempt to obtain remission was considered appropriate, Statistical methods. Randomizations were balanced by minimization. Remission rates and reasons for failure to achieve CR were comclinicians could either continue with courses 3 and 4 as per protocol or could give alternative therapy. After completing protocol chemopared using standard chi-squared tests. Kaplan-Meier life-tables were constructed for survival data and were compared by means of the logtherapy, it was recommended that patients with an HLA-matched sibling donor should then proceed to allogeneic transplant (allorank test, with surviving patients being censored at September 1, 1995, when follow-up was up-to-date for all but 25 patients (the small number BMT) while the remainder should be randomized between either A-BMT or stopping treatment (with A-BMT reserved for second of patients lost to follow-up are censored at the date they were last known to be alive The following definitions are also used: overall survival is the time from entry to death; for remitters, disease-free survival (DFS) Hodgkin's disease, 2 prior chronic myeloid leukemia, 2 prior is the time from CR to first event (either relapse or death in CR); lymphoma, and 20 prior other hematologic disorders. FAB type 10, 11 was reviewed centrally in 64% of patients, the referring center classification being used in the remaining pa- protocol. All analyses are, however, by allocated treatment ted on DAT after course two versus 21% with ADE and a third (or, in a few cases, fourth) course achieved a CR in a (ie, are ''intention-to-treat''), so lack of compliance cannot affect the treatment group that a patient is in.
further 8% with DAT and 5% with ADE. There was slightly more resistant disease with DAT (11%) than with ADE (9%, Remission rate. The overall CR rate was 82%, and it was 91% for children, 85% for adults aged 15 to 34, and P Å .07), while 8% of DAT patients and 9% of ADE patients suffered induction death (P Å .9). 77% for adults aged 35/ ( Table 3 ). The induction death rate was 9% overall, increasing from 5% in children to 12% in Deaths in CR. There was a slightly higher death rate in CR during consolidation therapy following ADE (9%) the over 45-year age group. Overall, 10% of patients had resistant disease and this also increased with age from 7% compared with DAT (6%) (P Å .06) ( Table 4 ). This excess was not related to any particular course of therapy. Infection in children to 15% at age 45/. There was no significant difference in CR rate between those allocated DAT (81%) and hemorrhage were the main causes of death in CR, but both neutrophil and platelet recovery were both slightly and those allocated ADE (83%, P Å .3), nor was there any difference in the number of courses required to achieve CR. quicker in the ADE arm (see below). Nor were there any differences between the two arms in nonhematologic toxicity Seventy percent of those remitting with DAT achieved CR after one course versus 74% with ADE, a further 22% remitafter courses 3 and 4. Median hospital inpatient stay was the same for DAT and ADE at 27, 22, 23, and 23 days after courses 1 to 4, respectively. There were 231 allogeneic and 212 autologous BMTs DISCUSSION performed in first CR. Procedural mortality did not differ following DAT or ADE induction: after allo-BMT it was
The MRC AML10 trial is the largest trial of therapy for AML reported to date. Its overall results are better than in 22% (26 of 117) with DAT and 22% (25 of 114) with ADE; after A-BMT, it was 14% (15 of 106) with DAT and 11% any previously reported large series of younger (age õ56 years) patients with AML, with 42% of all patients and (12 of 106) with ADE.
DFS, relapses, and survival. Among those who achieved over half of all children surviving more than 6 years from diagnosis (Fig 3 ; Table 5 ). However, outcome was not mate-CR, DFS at 6 years was 42% ({4) for patients allocated DAT and 43% ({4) for those allocated ADE (P Å .8) (Fig  rially influenced by the induction regimen given, and the remission rate, speed of remission attainment, DFS, relapse 2). If deaths in first CR are ignored, the relapse risk in the two groups was also very similar at 50% ({5) for DAT and rates, and overall survival were not significantly different between DAT and ADE (Tables 3 and 4 ; Fig 2 and 3 ). 49% ({4) for ADE at 6 years (P Å .6). Finally, overall survival from entry for all patients in the two groups was Subgroup analyses likewise found no convincing significant differences (Tables 5 and 6 ) -undue weight should not be identical at 40% ({4) at 6 years for both DAT and ADE (P Å .9) (Fig 3) .
attached to the apparent benefit of ADE in patients with secondary AML because with multiple subgroup compariRelative efficacy of induction schedules in different patient subsets. Analysis of survival by age group (Table 5) or by sons, P values of borderline significance could very easily arise by chance. The only other apparent difference was a FAB subtype (Table 6 ) showed no differences between thioguanine and etoposide in any subset (none of the 27 comparitrend toward a slightly higher rate of resistant disease on DAT (11%) compared with ADE (9%), but even this failed sons in Table 6 is significant). Mortality in the two treatment groups was also analyzed with regard to four other features to reach conventional statistical significance (P Å .07). Analysis of toxicity showed a ''swings and roundabouts'' at presentation and, again, no significant influence of gender, performance status, cytogenetic group, or white blood cell effect, with patients receiving DAT taking slightly longer to recover from pancytopenia (Table 7 ) (although the median count was found. Patients with secondary AML fared worse than those with de novo disease (CR rates: 67% v 83%, P number of days in hospital was not affected), whereas patients receiving ADE had slightly more nausea, alopecia, õ .0001; DFS at 5 years: 31% v 44%, P Å .001; overall survival at 5 years: 25% v 43%, P õ .0001). There was no mucositis, and diarrhea. There was some suggestion of a slightly higher risk of death in CR during consolidation in difference in CR rates between DAT (68%) and ADE (67%) in patients with secondary AML, but DFS at 5 years was the ADE group than in the DAT group (9% v 6%), mainly because of a small excess of deaths from infection and hemsomewhat better with ADE (41% v 25%, P Å .04), as was orrhage (Table 4) . Because there was no greater toxicity 45 or over it was 76%. Long-term outcome was similarly good, with 56% of children still alive 6 years after entry, (either hematologic or nonhematologic) after courses 3 and 4 with ADE, this may well be a chance finding because of with the corresponding figure for patients aged 45 or over being 35%. The DFS and overall survival curves (Figs 2 and small numbers.
The absence of any material differences in outcome be-3) show clear plateaus beyond year 4, suggesting that over half of the children and about a third of the adults entered tween the DAT and ADE regimens raises the question as to whether thioguanine and etoposide are equally effective, or in AML10 may have been cured of their AML. Furthermore, these results have been obtained in a multicenter trial, in equally ineffective, when added to daunorubicin plus Ara-C. There have been two previous randomized trials that have which patients were entered not only from large hospitals with much experience of treating AML, but also from many investigated the effect of adding either thioguanine 12 or etoposide 13 to the induction regimen for AML. Preisler's series smaller centers that only see a few cases each year. It may be that the adoption of two courses of DAT or ADE (irreconsisted of 668 patients who were randomly assigned to three initial therapy groups. They received either 7 days of spective of whether CR was achieved after one course) and the use of two intensive consolidation courses were factors cytarabine and 3 days of daunorubicin or the same regimen with thioguanine. The third group received 10 days of cytarain the improved outcome in this study.
In conclusion, we have found no evidence that an etopobine and 3 days of daunorubicin. The remission rates were 53%, 57%, and 57% for the three groups (P Å .6). There was side-containing regimen (ADE) is any better than the previously standard MRC thioguanine regimen (DAT). In parno demonstrable difference in toxicity and no statistically significant difference in remission duration between patients ticular there was no additional benefit from the use of etoposide rather than thioguanine in patients with monocytic treated on the three induction arms. Bishop's study included 264 adults who were randomized to receive either cytarabine leukemias. The regimens are broadly equivalent with regard to toxicity, efficacy, and resource usage, and could thus be by continuous infusion for 7 days and 3 days of daunorubicin or the same regimen with the addition of etoposide 75 mg/ used interchangeably. The question as to whether or not the addition of either etoposide or thioguanine to a standard m 2 per day for 7 days. The remission rate was 56% without etoposide and 59% with it. Survival was similar in the two daunorubicin-cytarabine induction regimen is beneficial will have to await further randomized study. arms but there was significantly improved remission duration with etoposide (mean 18 v 12 months, P Å .01). These two ACKNOWLEDGMENT trials were too small to provide conclusive evidence as to
We are grateful to the clinicians who entered their patients into whether the addition of a third drug is beneficial, although MRC AML10 and for their wholehearted support, without which in both studies the three-drug regimen did slightly better. lar, had specific activity in the monocytic subtypes of acute monocytic leukemia. 9, 14 This finding was considered to be 
